The U.S. Food and Drug Administration declined to approve AbbVie’s experimental wrinkle treatment, trenibotulinumtoxinE (trenibote), on April 23 2026, citing manufacturing concerns that require additional information from the company.
The FDA’s request focused on the manufacturing process; it did not raise safety or efficacy issues, indicating that the product’s clinical profile remains intact while the production system must meet current good manufacturing practice standards.
The decision removes a potential new product from AbbVie’s aesthetics portfolio, which already includes well‑established brands such as Botox Cosmetic and Juvederm. The portfolio was significantly expanded when AbbVie acquired Allergan in 2020, and the loss of trenibote delays a new revenue stream that could have broadened the company’s facial‑aesthetics offering.
AbbVie plans to submit a response to the FDA’s comments in the coming months and is continuing regulatory reviews of the product in other countries, signaling a sustained global strategy for the treatment.
In related corporate news, AbbVie’s Q1 2026 earnings are scheduled for April 29. Preliminary guidance has been revised to an adjusted diluted EPS of $2.56–$2.60, down from the earlier $2.97–$3.01 range, due to a $744 million acquired in‑process R&D and milestones expense that is expected to reduce EPS by $0.41. The full‑year 2026 adjusted diluted EPS guidance was also lowered to $13.96–$14.16. Executive Vice President of Research and Development Roopal Thakkar said, “We strongly believe trenibotulinumtoxinE is an important innovation in botulinum toxin science, with the potential to expand options for patients interested in facial aesthetics.”
The FDA rejection represents a setback for AbbVie’s aesthetics growth, delaying the launch of a product that could have added a new revenue stream. However, because the issue is manufacturing‑related rather than clinical, the company may be able to address the deficiencies and resubmit the application, preserving the long‑term potential of trenibote while maintaining confidence in its broader aesthetics strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.